Resources from the same session
656MO - The HER2-targeting ADC SHR-A1811 in HER2-expressing/mutated advanced non-breast solid tumors (STs): Results from the global phase I study
Presenter: Yiming Zhao
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
657MO - Recommended phase II dose (RP2D) selection and pharmacodynamic (PD) data of the first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients (pts) with advanced HER2-expressing solid tumors
Presenter: Bob Li
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
LBA34 - Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study
Presenter: Funda Meric-Bernstam
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
658MO - Phase I study of SHR-A2009, a HER3-targeted ADC, in advanced solid tumors
Presenter: Yi-Long Wu
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
Invited Discussant 656MO, 657MO, LBA34 and 658MO
Presenter: Pamela Munster
Session: Mini oral session - Developmental therapeutics
Resources:
Slides
Webcast
659MO - Preliminary results from a phase I/II study of 9MW2821, an antibody-drug conjugate targeting nectin-4, in patients with advanced solid tumors
Presenter: Jian Zhang
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
660MO - First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: Preliminary results of a phase I study (SGNB7H4V-001)
Presenter: Cesar Perez
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
LBA35 - BNT211-01: Interim results from a repeat dose escalation study of CLDN6 CAR-T cells manufactured with an automated process ± a CLDN6-encoding CAR-T cell-amplifying RNA Vaccine (CARVac)
Presenter: John Haanen
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
661MO - Anti-tumor activity of belvarafenib in combination with cobimetinib in patients with metastatic solid tumors harboring BRAF fusions or BRAF class II/III mutation
Presenter: Tae Won Kim
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
662MO - Phase I, multi-center, dose-escalation and dose-expansion study of IMP7068, a WEE1 inhibitor, in patients with advanced solid tumors
Presenter: Chia-Chi Lin
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast